45th week of 2015 patent applcation highlights part 22 |
Patent application number | Title | Published |
20150315186 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS - The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. | 2015-11-05 |
20150315187 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 - The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer. | 2015-11-05 |
20150315188 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION - Hydrogenated pyrido[4,3-b]indoles and pyrido[3,4-b]indoles are described. The compounds may bind to and are adrenergic receptor α | 2015-11-05 |
20150315189 | 18F-LABELLED FOLATES - The present invention is directed towards a new method of synthesis of | 2015-11-05 |
20150315190 | PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS, THEIR PREPARATION AND USE AS SIGMA LIGANDS - New pyrazolo[3,4-d]pyrimidine compounds having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for preparing these compounds, to compositions comprising them and to their use as medicaments. | 2015-11-05 |
20150315191 | 4-Position Substituted Pyrazolopyrimidine Derivative, And Use Thereof In Drug Preparation - The invention belongs to the technical field of organic synthetic drugs, and particularly relates to a pyrazolopyrimidine derivative and a preparation method and medical uses thereof. The invention provides a new pyrazolopyrimidine derivative mainly having position 4 substituted, i.e., position substituted by Y in formula I. The pyrazolopyrimidine derivative of the invention has a structural formula I as follows: | 2015-11-05 |
20150315192 | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS, THEIR PREPARATION AND USE AS SIGMA RECEPTORS LIGANDS - The present invention relates to new substituted pyrazolo[3,4-d]pyrimidine compounds, having a great affinity for sigma receptors, especially sigma-1 receptor, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments. | 2015-11-05 |
20150315193 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES - The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VII). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. | 2015-11-05 |
20150315194 | CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B] PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT - Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyi-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyljbenzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyi-N-{4-[(4-methyl piperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein. The instant application is directed to novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyi-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl}phenyl}benzamide and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyi-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, compositions comprising such crystalline forms, and to methods of their preparation and use. | 2015-11-05 |
20150315195 | AN IMPROVED PROCESS FOR MAKING ZILPATEROL - This invention generally relates to processes for making zilpaterol and salts thereof, as well as processes for making intermediates that, interalia, may be used to make zilpaterol and salts thereof. | 2015-11-05 |
20150315196 | UNSYMMETRICAL PYRROLOBENZODIAZEPINES-DIMERS FOR USE IN THE TREATMENT OF PROLIFERATIVE AND AUTOIMMUNE DISEASES - A compound of formula I: | 2015-11-05 |
20150315197 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE - The present invention provides a compound having the structure: | 2015-11-05 |
20150315198 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS - In one aspect this invention relates generally to compounds of Formula: | 2015-11-05 |
20150315199 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS - The present invention is directed to novel compounds of formula I | 2015-11-05 |
20150315200 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (I): | 2015-11-05 |
20150315201 | INDOLE AND INDOLINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF - The disclosure relates to indole-type piperidine compounds, indoline-type piperidine compounds and related piperidine-type bicyclic compounds containing a five-membered nitrogen-containing ring (e.g., pyrrole or dihydropyrrole) fused to a heteroaryl ring, compositions comprising an effective amount of such compounds, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of an indole-type piperidine compound, indoline-type piperidine compound or related piperidine-type bicyclic compound containing a five-membered nitrogen-containing ring (e.g., pyrrole or dihydropyrrole) fused to a heteroaryl ring. | 2015-11-05 |
20150315202 | CHLORIN DERIVATIVE USEFUL IN PHOTODYNAMIC THERAPY AND DIAGNOSIS - The present invention relates to chlorin e4 sodium and a process for its preparation. Chlorin e4 sodium is suitable for use in photodynamic therapy, cytoluminescent therapy and photodynamic diagnosis, for example for treating or detecting a tumour. The present invention also relates to a pharmaceutical composition comprising chlorin e4 sodium, to the use of chlorin e4 sodium in the manufacture of a phototherapeutic or photodiagnostic agent, and to a method of photodynamic therapy, cytoluminescent therapy or photodynamic diagnosis, for example for treating or detecting a tumour. | 2015-11-05 |
20150315206 | HALICHONDRIN B ANALOGS - The invention includes halichondrin B analogs having pharmaceutical activity; in some cases, crystalline forms thereof, and in some cases, halichondrin B analogs having a further utility as synthetic intermediates. | 2015-11-05 |
20150315207 | Novel Heterocyclic Compound Classes for Signaling Modulation - The invention relates to compounds of Formulas I-VII (or pharmaceutically acceptable salts thereof) as defined herein, pharmaceutical compositions thereof, and their use in manufactures and methods for modulating cellular signaling pathways and biological processes associated therewith including inhibition of kinase activity such as PI-3 kinase or inhibition of bromodomain proteins or both at the same time as well as to therapeutic methods for treating a disease associated with aberrant PI3K and/or bromodomain proteins. | 2015-11-05 |
20150315208 | BENZAZEPINE COMPOUND - Provided is a compound which is useful as an agent for treating or preventing 5-HT | 2015-11-05 |
20150315209 | HETEROCYCLIC COMPOUND - An object of the present invention is to provide a compound having a superior CH24H inhibitory action, which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. The present invention relates to a compound represented by the formula: | 2015-11-05 |
20150315210 | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS - This invention relates to novel fused quinazoline derivatives of Formula I as c-Met inhibitors, their synthesis and uses for treating c-Met mediated disorders. | 2015-11-05 |
20150315211 | SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS - This invention relates to compounds which selectively bind to the survival protein MCL-1 with high affinity and selectivity, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for modulating MCL-1 activity and for treating hyperproliferative disorders, angiogenesis disorders, cell cycle regulation disorders, autophagy regulation disorders, inflammatory disorders, and/or infectious disorders and/or for enhancing cellular engraftment and/or wound repair, as a sole agent or in combination with other active ingredients. | 2015-11-05 |
20150315212 | SUBSTITUTED 1,4-DITHIINE DERIVATIVES AND THEIR USE AS FUNGICIDES - The present invention relates to substituted 1,4-dithiine derivatives of formula I as defined in the description, and the N-oxides, and salts thereof, their preparation and intermediates for preparing them. The invention also relates to the use of these compounds for combating harmful fungi and seed coated with at least one such compound and also to compositions comprising at least one such compound. | 2015-11-05 |
20150315213 | TRIS(TRIMETHYL SILOXY)SILANE VINYLIC MONOMERS AND USES THEREOF - The invention provides a TRIS-containing vinylic monomer which comprises one sole (meth)acryloyloxy group and a tris(trimethylsiloxy)silyl group covalently linked to the ethylenically-unsaturated group through a polyoxyethylene linker. The present invention is also related to a polymer, an actinically-crosslinkable silicone-containing prepolymer, a silicone hydrogel polymeric material, or a silicone hydrogel contact lens, which comprises monomeric units derived from a TRIS-containing vinylic monomer of the invention. In addition, the invention provides a method for making a TRIS-containing vinylic monomer of the invention. | 2015-11-05 |
20150315214 | METHOD FOR THE HYDROSILYLATION OF A SILOXANE PHOTOCATALYSED BY A POLYOXOMETALATE COMPOUND - The invention concerns a method of hydrosilylation between a siloxane compound (A) comprising at least one hydrogen atom bonded to a silicon atom and an unsaturated compound (B) comprising at least one alkene function and/or at least one alkyne function, the method being characterized in that it is catalysed by a photocatalyst selected from among the polyoxometalates. | 2015-11-05 |
20150315215 | COMPOSITION AND METHOD FOR LOW TEMPERATURE CHEMICAL VAPOR DEPOSITION OF SILICON-CONTAINING FILMS INCLUDING SILICON CARBONITRIDE AND SILICON OXYCARBONITRIDE FILMS - Silicon precursors for forming silicon-containing films in the manufacture of semiconductor devices, such as films including silicon carbonitride, silicon oxycarbonitride, and silicon nitride (Si | 2015-11-05 |
20150315216 | PHOSPHATE COMPOSITION - A process for the preparation of a composition comprising amine-containing phosphate glycerides including: phosphorylating a solution which comprises mixed glycerides that contain fatty acid portions and an amine under conditions which are substantially water-free and under which said phosphorous pentoxide reacts with reactive constituents in said solution to form said amine-containing phosphate glycerides and a lubricating composition comprising a lubricant, the aforesaid composition in an amount which improves the properties of the lubricating composition, and optionally one or more other constituents which improve the properties of the lubricating composition. | 2015-11-05 |
20150315217 | Method of Making Small Liposomes - Liposomes of constrained particle size are prepared by substantially continuously mixing substantially continuously flowing streams of water, and of an organic solvent contain lipid(s) capable of forming liposomes, and cooling the mixture so liposomes form, the ratio of the flow rate of the stream of water to the flow rate of the stream of organic solvent, and the rate of cooling of said mixture, being controlled so as to obtain a preparation of liposomes such that at least about 90% of the liposomes are of a particle size less than about 200 nm | 2015-11-05 |
20150315218 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS - This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection: | 2015-11-05 |
20150315219 | NOVEL CYCLIC PHOSPHINATE DERIVATIVES AND METHOD OF PREPARING THE SAME - Provided are novel cyclic phosphinate derivatives and a method of preparing the same, and more particularly, cyclic phosphinate derivatives including benzoxaphosphole oxide derivatives and benzoxaphosphorin oxide derivatives, and a method of preparing the same. The cyclic phosphinate derivative according to the present invention may have pharmacological and physiological activities, be used as the basic skeleton of the natural material, and be used in development of a new drug, and synthesis of various medicines. In addition, with the method of preparing a cyclic phosphinate derivative according to the present invention, various cyclic phosphinate derivatives may be prepared with high yield through a simple synthetic process by performing an intramolecular carbon-oxygen coupling reaction on the phosphinic acid derivative in the presence of a palladium (Pd) catalyst, an oxidant, and a base. | 2015-11-05 |
20150315220 | NOVEL DERIVATIVES OF OXAZAPHOSPHORINES THAT ARE PRE-ACTIVATED, USE AND METHOD OF PREPARATION - The present invention relates to novel derivatives of oxazaphosphorines that are pre-activated, to the methods for preparing same, to the pharmaceutical compositions containing same and to the therapeutic use thereof, in particular for treating cancer. | 2015-11-05 |
20150315221 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS - The present invention relates to disulfide masked prodrug compounds, compositions and methods that are amenable to bioactivation by a reducing agent such as glutathione. Such disulfide based compounds, compositions, and methods can be useful, for example, in providing novel prodrugs for use as therapeutics. | 2015-11-05 |
20150315222 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - A compound that has the structure according to Formula M(L | 2015-11-05 |
20150315223 | Ruthenium Complexes Comprising an Asymmetrical Unsaturated N-Heterocyclic Diaminocarbene - The invention relates to a ruthenium alkylidene complex comprising a 1-aryl-3-cycloalkyl-imidazolin-2-ylidene ligand, the cycloalkyl group of said 1-aryl-3-cycloalkyl-imidazolin-2-ylidene ligand being a cyclic secondary aliphatic alkyl. | 2015-11-05 |
20150315224 | METHOD FOR PRODUCING AQUEOUS PREPARATIONS OF COMPLEXES OF PLATINUM GROUP METALS - The invention relates to a method for producing aqueous preparations of complexes of platinum group metals (PGM) Pt, Pd, Rh and Ir having the general formula [M | 2015-11-05 |
20150315225 | PURIFICATION OF STAPHYLOCOCCUS AUREUS TYPE 8 CAPSULAR SACCHARIDES - The invention provides a method for releasing capsular polysaccharide from | 2015-11-05 |
20150315226 | DISULFIDE MASKED PRODRUG COMPOSITIONS AND METHODS - The present invention relates to disulfide masked prodrug compounds, compositions and methods that are amenable to bioactivation by a reducing agent such as glutathione. Such disulfide based compounds, compositions, and methods can be useful, for example, in providing novel prodrugs for use as therapeutics. | 2015-11-05 |
20150315227 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF - Aspects of the present disclosure include compositions that make use of phosphorus and/or nucleobase protecting groups which find use in the synthesis of long polynucleotides. Phosphorus protecting groups are provided that help increase the stepwise coupling yield and/or phosphorous protecting groups that can be removed during the oxidation step. Amidine nucleobase protecting groups are provided that find use in the subject compositions and methods which provides for e.g., increased resistance to depurination during polynucleotide synthesis. In some instances, the methods and compositions disclosed herein utilize a combination of the phosphorus and amidine nucleobase protecting groups in the synthesis of polynucleotides having a sequence of 200 or more monomeric units in length. Also provided are methods for synthesizing a polynucleotide (e.g., a DNA) using one or more compounds disclosed herein. | 2015-11-05 |
20150315228 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF - Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. | 2015-11-05 |
20150315229 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID - In this method, an oligonucleotide is prepared by using, as a synthesis unit, a novel nucleoside monomer compound represented by formula (I) [wherein X, R | 2015-11-05 |
20150315230 | NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME - The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds. | 2015-11-05 |
20150315231 | New Steroids Having Increased Water Solubility and Resistance Against Metabolism and Methods For Their Production - Steroid compounds having increased resistance against metabolism and increased water solubility are disclosed, together with methods for their production. These substances are suitable for the manufacture of pharmaceuticals for the treatment of steroid related or steroid induced CNS disorders and for use in methods of prevention, alleviation or treatment of such disorders. | 2015-11-05 |
20150315232 | Refolding Proteins Using a Chemically Controlled Redox State - A method of refolding proteins expressed in non-mammalian cells present in concentrations of 2.0 g/L or higher is disclosed. The method comprises identifying foe thiol pair ratio and the redox buffer strength to achieve conditions under which efficient folding at concentrations of 2.0 g/L or higher is achieved and can be employed over a range of volumes, including commercial scale. | 2015-11-05 |
20150315233 | USE OF YAM GLYCOPROTEIN FOR IMPROVING ACTIVITY OF MITOCHONDRIAL OXIDATIVE METABOLIC ENZYME OF BRAIN CELL - A method for preparing for glycoprotein in Chinese yam to enhance the activity of metabolic enzymes of brain mitochondria may include steps of: grinding the Chinese yam into fine powers; adding water into the fine powers and heating up to 50-100° C. to form a mixture, and the amount of water is 2 to 5 times as much as the Chinese yam; extracting the mixture twice, and combining the two extracting solutions; concentrating the extracting solution and adding 95% ethyl alcohol to obtain a first mixed liquid with 60-75% ethyl alcohol concentration and white sediments start to appear; separating the white sediments from a first supernate; adding 95-98% ethyl alcohol in the first supernate to obtain a second mixed liquid with 90-95% ethyl alcohol concentration and brown emplastic sediments start to appear; removing a second supernate; and collecting and drying the brown sediments to obtain brown glycoprotein in Chinese yam. | 2015-11-05 |
20150315234 | MYOBLAST DIFFERENTIATION PROMOTER - A peptide selected from the group consisting of Ala-Hyp-Gly, Hyp-Gly-Pro, Leu-Hyp, Glu-Hyp, Gly-Pro-Hyp, Pro-Ala, Hyp-Gly and Pro-Hyp, or a pharmaceutically acceptable salt thereof has a myoblast differentiation promoting effect superior to conventional arts. | 2015-11-05 |
20150315235 | Combinatorial Synthesis of Libraries of Macrocyclic Compounds Useful in Drug Discovery - A library of macrocyclic compounds of the formula (I) | 2015-11-05 |
20150315236 | PEPTIDE - The invention provides a peptide comprising or consisting of FSY and variants thereof, particularly comprising or consisting of the sequence FTY, nucleic acids encoding said peptides and pharmaceutical and nutraceutical compositions comprising said peptide(s) and/or nucleic acids. Also provided is the use of such a peptide in therapy and in vitro methods of ACE-inhibition. | 2015-11-05 |
20150315237 | NMDA Receptor Modulators and Uses Thereof - Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed. | 2015-11-05 |
20150315239 | METHOD OF INDUCING AN IMMUNE RESPONSE BY ADMINISTERING WDRPUH EPITOPE PEPTIDES - The present invention provides peptides containing the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides containing the above-mentioned amino acid sequences in which 1, 2, or several amino acid(s) are substituted, deleted, inserted or added, but still have cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors, which drugs containing these peptides. The peptides of the present invention can also be used as vaccines. | 2015-11-05 |
20150315240 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES - The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides. | 2015-11-05 |
20150315241 | Antibiotic Peptides - This invention concerns novel antibiotic peptide and peptide derivates, especially for use in medicine. Further, the invention relates to compositions and methods for killing microbes, like bacteria or fungus, and methods to treat microbial infections. The invention further relates to a method for drug screening analysis. The peptides and peptide derivates have the general formula Sub | 2015-11-05 |
20150315242 | SELF-ASSEMBLING PEPTIDE AND PEPTIDE GEL WITH HIGH STRENGTH - Provide are a peptide gel with practically sufficient mechanical strength and a self-assembling peptide capable of forming the peptide gel. The self-assembling peptide is formed of the following amino acid sequence: a | 2015-11-05 |
20150315243 | METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN ORGANIC COMPOUNDS - The present invention relates to methods for forming dicarba bridges in organic compounds. This involves the use of a pair of complementary metathesisable groups on the organic compound, and subjecting the compound to cross-metathesis under microwave radiation conditions. In an alternative, the compounds contain a turn-inducing group between the pair of cross-metathesisable groups to facilitate the cross-metathesis. | 2015-11-05 |
20150315244 | Peptides for Treating Cancer - The present disclosure relates to peptides for treating cancer, wherein the peptides suppress BRCA1-IRIS expression or activity. The peptides may include an amino acid sequence as set forth in SEQ ID NO: 1 and/or SEQ ID NO: 2. Further, the present disclosure provides methods for treating cancer, wherein the cancer may be breast or ovarian cancer, including administering one of said peptides to a subject in need thereof. | 2015-11-05 |
20150315245 | Peptide Compounds and Methods of Production and Use Thereof - Peptide compounds based on the CAP37 (cationic antimicrobial protein of M | 2015-11-05 |
20150315246 | SCALABLE PROCESS FOR PROTEIN PURIFICATION - The invention provides a process for the purification recombinantly expressed, self-assembled VLP from the homogenate of a bacterial host, wherein the process can be scaled up to a commercial production scale in a cost effective manner. The process comprises a first chromatography using an anion exchange matrix, a second chromatography using hydroxyapatite and, optionally, a size exclusion chromatography. VLP preparations obtained by the process of the invention are essentially free of endotoxin contaminations. | 2015-11-05 |
20150315247 | High-affinity peptide-based anticancer vaccination to overcome tumor resistance to immunostimulatory antibodies and to identify TCRs that can be used successfully in adoptive T cell therapy - The invention provides a methodology to use cancer vaccination to overcome tumor resistance to immunostimulatory antibodies. Our cancer vaccination approach relies on targeting mutant tumor-specific peptides that have high affinity for the major histocompatibility complex. Treatment with bacteria expressing high affinity tumor-specific peptides combined with anti-PD-L1 monoclonal antibody can eradicate long-established tumors resistant to anti-PD-L1 and anti-CTLA-4 alone. In addition, we discovered that adoptive transfer of T cells with this same vaccine-generated T cell receptor specificity can also eradicate long-established tumors. These results demonstrate that cancer vaccination approaches should target peptides with high peptide-MHC affinity to (i) overcome tumor resistance to immunostimulatory antibodies and (ii) identify T cell receptors that can be used successfully for adoptive T cell transfer. | 2015-11-05 |
20150315248 | CLOSTRIDIUM DIFFICILE POLYPEPTIDES AS VACCINE - The invention provides methods, proteins, nucleic acids and antibodies for preventing or treating a | 2015-11-05 |
20150315249 | CROSSLINKED THERMOSET RESINS AND METHODS THEREOF - The present invention relates to a method of making a crosslinked thermoset resin. One embodiment of this method comprises: (i) separating a plant-derived flour mixture into a protein fraction comprising proteins and a carbohydrate fraction comprising carbohydrates; (ii) subjecting the carbohydrate fraction to an oxidizing agent to yield oxidized carbohydrates comprising aldehyde functional groups or both aldehyde functional groups and carboxyl functional groups; and (iii) reacting the oxidized carbohydrates with the protein fraction under conditions effective to crosslink the proteins, thereby yielding a crosslinked thermoset resin. The present invention also relates to a crosslinked thermoset resin and composites, nanofiber membranes, and adhesives comprising the crosslinked thermoset resin. | 2015-11-05 |
20150315250 | TRANSGENIC PLANTS WITH INCREASED TRACE ELEMENT CONTENTS AND METHODS FOR PRODUCING THE SAME - The present invention relates to a transgenic plant with increased trace element contents and a method for producing the same. In particular, the transgenic plant is incorporated by a polynucleotide encoding an iron-regulated protein 1 (IRP1/IMA1) or IRP1-like (IRL/IMA3) polypeptide, which facilitate uptake and circulation of the trace elements into the plant. Also provided is a method for treating trace element deficiency by administrating to a subject in need a composition comprising a transgenic plant as described or an edible tissue or part thereof. | 2015-11-05 |
20150315251 | SEQUENCE-DETERMINED DNA FRAGMENTS ENCODING PEPTIDE TRANSPORT PROTEINS - The present invention provides DNA molecules that constitute fragments of the genome of a plant, and polypeptides encoded thereby. The DNA molecules are useful for specifying a gene product in cells, either as a promoter or as a protein coding sequence or as an UTR or as a 3′ termination sequence, and are also useful in controlling the behavior of a gene in the chromosome, in controlling the expression of a gene or as tools for genetic mapping, recognizing or isolating identical or related DNA fragments, or identification of a particular individual organism, or for clustering of a group of organisms with a common trait. | 2015-11-05 |
20150315252 | PROTEIN ENRICHED MICROVESICLES AND METHODS OF MAKING AND USING THE SAME - The present invention relates to a microvesicle comprising: (i) a membrane-associated protein comprising at least one first dimerization domain, (ii) a carrier protein comprising at least one second dimerization domain, and (iii) a solute that binds to the carrier protein, wherein the solute is selected from the group of: DNA, RNA, protein, carbohydrate, ribosomes, mitochondria, and small molecules. Also provided are cells, reagents and kits that find use in making the microvesicles, as well as methods of using the microvesicles, e.g., in research and therapeutic applications | 2015-11-05 |
20150315253 | PEPTIDES AND COMPOSITIONS FOR PREVENTION OF CELL ADHESION AND METHODS OF USING SAME - Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of YDYNWY, YDYNLY, FDYNFY, FDYNLY, FDYNWY, YDWNLY, YDWHLY and WDYNLY, extracted from organisms such as aquatic organisms and mossor any other sequence described herein, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface. | 2015-11-05 |
20150315254 | LUTZOMYIA LONGIPALPIS POLYPEPTIDES AND METHODS OF USE - Substantially purified salivary | 2015-11-05 |
20150315255 | IMMUNE MODULATOR FOR IMMUNOTHERAPY AND VACCINE FORMULATION - A recombinant Flagrp170 protein and pharmaceutical compositions comprising a Flagrp170 protein and related molecules encoding same, and cells presenting such a protein are provided. The Flagrp170 protein comprises an NF- | 2015-11-05 |
20150315256 | Anti-Inflammatory Pharmaceutical Products - Polypeptides having homology to regions of the N-terminal 50 residues of human Annexin 1 are provided for medical use as anti-inflammatory agents. Some of the polypeptides have homology to the N-terminal 48 residues of human Annexin 1, especially to residues 2-48 and 11-48 thereof. In some embodiments, properties of these compounds are improved by at least one modification at residues corresponding to residues 11, 22, 25 and/or 36 of human Annexin 1, and/or by C-terminal amidation of the polypeptide. Analogs of amino acids 2-26 of human Annexin 1, especially acetylated at the N-terminus and/or amidated at the C-terminus and having modifications at 11 and/or 22 are also disclosed for medical use as anti-inflammatory agents. | 2015-11-05 |
20150315257 | UROCORTIN 2 ANALOGS AND USES THEREOF - Disclosed are polypeptides that are analogs of urocortin 2 that have pharmacological activity similar to urocortin 2 but have improved water solubility compared to urocortin 2, and pharmaceutical compositions of the polypeptides of the present invention. Also disclosed are polynucleotides encoding the polypeptides, and methods of treating pathophysiological states employing pharmaceutical compositions of the polypeptides and polynucleotides of the present invention. In addition, disclosed are vectors and host cells that include a nucleic acid encoding a polypeptide of the present invention, and kits that include pharmaceutical compositions of the present invention. | 2015-11-05 |
20150315258 | GENETICALLY ENCODED CALCIUM INDICATORS AND METHODS OF USE - Genetically encoded calcium indicator (GECI) polypeptides and the nucleic acid molecules encoding such polypeptides are provided. In addition, methods of using such nucleic acids and polypeptides in methods of screening for agonists or antagonists of G-protein coupled receptor (GPCR) or ion channels and methods of monitoring neural activity also are provided. | 2015-11-05 |
20150315259 | METHOD OF PRODUCING A RECOMBINANT PEPTIDE - Methods of producing a recombinant peptide, such as vessel dilator peptide (VSDL), are disclosed, including a particular method involving expressing a fusion polypeptide comprising concatemeric repeats of the peptide wherein the peptide is flanked by peptide cleavage sites, and cleaving the fusion polypeptide at the peptide cleavage sites with a cleaving agent(s) so as to release the peptide from the fusion polypeptide. Expression constructs and host cells for producing the fusion polypeptide and purification methods for the recombinant peptide are also disclosed. | 2015-11-05 |
20150315260 | EXENDIN-4 DERIVATIVES AS PEPTIDIC DUAL GLP-1/GLUCAGON RECEPTOR AGONISTS - The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake. | 2015-11-05 |
20150315261 | MEANS FOR TREATING HEART DISEASE - The invention pertains to a means for downregulating or inhibiting or mislocalizing CAR in a cardiac cell for treating/curing a patient who has suffered or is predisposed to suffering a myocardial infarction (MI) or preventing myocardial infarction or complications thereof. | 2015-11-05 |
20150315262 | NOVEL INTERLEUKIN-33 INHIBITORS - The present invention relates to novel inhibitors of IL-33. More specifically, it relates to a fusion protein of the soluble IL-33 receptor with the soluble IL-1RAcP as inhibitor of IL-33 activity. The invention relates further to the use of the inhibitor in treatment of IL-33-related diseases such as, but not limited to, asthma, atopic dermatitis and psoriasis. | 2015-11-05 |
20150315263 | MONOLITH-BASED PSEUDO-BIOAFFINITY PURIFICATION METHODS FOR FACTOR VIII AND APPLICATIONS THEREOF - The present disclosure relates to purification of Factor VIII protein and/or its fragments from various sources by employing monolith based pseudobioaffinity purification methods. In particular, L-histidine over CIM monolith [Histidine Ligand Affinity Chromatography (HLAC)] is used for the purification of wild-type factor VIII from plasma cryoprecipitate, recombinant B-domain deleted factor VIII (rBDD-FVIII) expressed in various host systems and recombinant factor VIII light chain expressed in | 2015-11-05 |
20150315264 | PROCESS FOR PURIFYING LACTOFERRIN FROM MILK AND PRODUCTS THEREOF - The invention provides a process for purifying lactoferrin from milk, the process comprising subjecting the milk to filtration to separate it into a retentate fraction comprising lactoferrin and a permeate fraction comprising growth factors and/or RNAses, wherein prior to and/or during filtration the milk is subjected to salt treatment such that growth factors and/or RNAses flow into the permeate. The invention also provides lactoferrin obtained from the process of the invention and uses thereof. | 2015-11-05 |
20150315265 | SECONDARY ANTIBODY DETECTED EPITOPE AND PREPARATION OF SAME - A method of preparing an epitope for a secondary antibody detected protein tag, comprising: constructing a expressing vector, comprising a nucleotide sequence for encoding the secondary antibody detected protein tag comprising at least one epitope selected from at least one primary antibody which is detected by corresponding secondary antibody; expressing the vector in a host cell; and obtaining the secondary antibody detected protein tag which is expressed in the host cell. Further, a method for constructing a protein molecular weight marker ladder, comprising constructing a plurality of recombinant protein tags with different molecular weights, wherein each the recombinant protein tag comprises at least one epitope of primary antibody. Besides, a secondary antibody detected protein tag comprises at least two peptide sequences of epitopes selected from primary antibodies of at least two different species. | 2015-11-05 |
20150315266 | HUMAN ANTIBODIES AGAINST RABIES AND USES THEREOF - Human monoclonal antibodies that specifically bind to rabies virus, antigen binding portions thereof, and methods of making and using such antibodies and antigen binding portions thereof for treating rabies virus in a subject, are provided herein. | 2015-11-05 |
20150315267 | A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-AB ANTIBODIES - This disclosure relates to the use of anti-Aβ antibody or antigen-binding fragment thereof to reduce brain amyloid plaques, or minimizes the occurrence of microhemorrhage during chronic dosing of an anti-Aβ antibody or antigen-binding fragment thereof. For example, the disclosure relates to the method of reducing brain amyloid plaques, comprising administering to a subject an anti-Aβ antibody or antigen-binding fragment thereof that binds to the same epitope as BIIB037 antibody, wherein the administration can reduce amyloid plaques in brain without affecting vascular amyloid, and wherein BIIB037 antibody binds to an epitope comprising amino acids 3-6 of Aβ. | 2015-11-05 |
20150315268 | ALTERNATIVE PATHWAY SPECIFIC ANTIBODIES FOR TREATING HEMOLYTIC DISEASES - A method of treating a hemolytic disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of an antibody that binds to a component of alternative pathway C3 convertase and selectively inhibits C3a, C5a, C3b, C5b, and C5b-9 produced exclusively by the alternative pathway, without inhibiting any of the classical pathway's ability to produce C3a, C5a, C3b, C5b, and C5b-9. | 2015-11-05 |
20150315269 | Breast Endothelial Cell Expression Patterns - To gain a better understanding of breast tumor angiogenesis, breast endothelial cells (ECs) were isolated and evaluated for gene expression patterns. When transcripts from breast ECs derived from normal and malignant breast tissues were compared, genes that were specifically elevated in tumor-associated breast endothelium were revealed. These results confirm that neoplastic and normal endothelium in human breast are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future. | 2015-11-05 |
20150315270 | ANTI-HUMAN VEGF ANTIBODIES WITH UNUSUALLY STRONG BINDING AFINITY TO HUMAN VEGF-A AND CROSS REACTIVITY TO HUMAN VEGF-B - Murine and humanized anti-human VEGF antibodies and uses are disclosed. The anti-human VEGF antibodies of the invention have higher binding affinity for human VEGF-A, are stronger inhibitors of the VEGF-A induced proliferation of endothelial cells in culture as compared with anti-human VEGF antibodies in the art. Moreover, these antibodies cross react with human VEGF-B. The antibodies of the invention inhibit tumor growth in vivo in greater extent than Bevacizumab (Avastin™) when administered at the same dosage | 2015-11-05 |
20150315271 | FORMULATIONS - The invention provides a formulation comprising a buffer with a pH from about 4.0 to about 6.0, proline and an effective amount of a polypeptide. The polypeptide can be an antibody. The specification also provides methods of preparing the formulation, a kit containing the formulation and methods of using the formulation. | 2015-11-05 |
20150315272 | Epitopes of IL-17A and IL-17F And Antibodies Specific Thereto - The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them. | 2015-11-05 |
20150315273 | SP35 Antibodies And Uses Thereof - Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody. | 2015-11-05 |
20150315274 | Anti-PD1 Antibodies and their Use as Therapeutics and Diagnostics - Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions. | 2015-11-05 |
20150315275 | ANTI-HUMAN B7-H4 ANTIBODIES AND THEIR USES - Anti-human B7-H4 antibody “6H3”, antigen-binding fragments, derivatives, and humanized variants thereof that are capable of immmospecifically binding to B7-H4, and the uses of such molecules in the diagnosis and the treatment of cancer and other diseases are disclosed. In preferred embodiments, the molecules are used to retard or prevent tumor growth, inhibit tumor-mediated suppression, eliminate tumors and/or deplete or block the activity of tumor-associated macrophages (“TAMs”) so as to alter their activity and/or decrease TAM-mediated immune suppression. | 2015-11-05 |
20150315276 | INHIBITOR OF INTEGRIN FOR THE TREATMENT OR PREVENTION OF TUMOURS - The present invention relates to inhibitors of alpha7 integrin for the treatment, suppression and/or prevention of tumours, to composition comprising inhibitors of alpha7 integrin for the treatment, suppression and/or prevention of tumours and to medical treatments comprising administering said inhibitors or compositions to a patient in need thereof, for the treatment, suppression and/or prevention of tumours. | 2015-11-05 |
20150315277 | DUAL-TARGET ANTIBODY TARGETING VEGFR-2 AND DLL4, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME - The present invention relates to a novel form of a dual-target antibody targeting VEGFR-2 and DLL4, a gene encoding the same, a recombinant expression vector including the gene, host cells transformed with the recombinant expression vector, a method of producing the dual-target antibody using the host cells, a pharmaceutical composition comprising the dual-target antibody. | 2015-11-05 |
20150315278 | Anti-Glypican-3 Antibody Having Improved Kinetics in Plasma - A method of modulating the plasma half-life of anti-glypican 3 antibody, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody that has a plasma half-life that has been modulated, a method of preparing the anti-glypican 3 antibody and a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient are provided. Disclosed is a method of modulating the plasma half-life of anti-glypican 3 antibody by modifying an amino acid residue that is exposed on the surface of the anti-glypican 3 antibody; and anti-glypican 3 antibody that has a plasma half-life that has been modulated by amino acid residue modification, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody, and a method of preparing the anti-glypican 3 antibody and producing a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient. | 2015-11-05 |
20150315279 | ANTIBODIES THAT BIND MEMBRANE-BOUND IL1RAP - Methods and compositions for binding to the membrane-bound form of IL1 RAP. In some embodiments, the invention provides an isolated antibody that binds the membrane bound fom1 of human IL1 RAP. In some cases, the isolated antibody that binds the membrane-bound form of human IL1 RAP does not bind, or does not substantially bind, the soluble form of human IL1 RAP. For example, in some cases, the isolated antibody that binds the membrane-bound form of human IL1RAP does not bind, or does not substantially bind the soluble form of human IL1RAP that is found in normal human serum. In some cases, the soluble form of human IL1 RAP comprises the sequence GNRCGQ. | 2015-11-05 |
20150315280 | PREVENTIVE OR REMEDY FOR INFLAMMATORY DISEASE - The present inventors obtained, from a phage library of human antibodies, an anti-mouse NR 10 neutralizing antibody-expressing BM095 clone that shows a strong proliferation-suppressing activity in an IL-31-dependent Ba/F3 cell proliferation assay system. When this anti-mouse NR 10 neutralizing antibody was administered to NC/Nga mice, a model of atopic dermatitis which is a mouse model of chronic dermatitis that arises as a result of repeated applications of picryl chloride, a mouse model of rheumatoid arthritis, and a mouse model of osteoarthritis, a significant effect of symptom suppression was observed. This revealed that the anti-NR 10 neutralizing antibody is indeed effective as a therapeutic agent for inflammatory diseases. In addition, the present inventors successfully obtained an anti-human NR 10 neutralizing antibody, providing extremely useful therapeutic agents with practical clinical applications. | 2015-11-05 |
20150315281 | ANTI-OX40 ANTIBODIES AND METHODS OF USING THE SAME - Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided. | 2015-11-05 |
20150315282 | ANTI-CD40 ANTIBODIES - The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same. | 2015-11-05 |
20150315283 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 2015-11-05 |
20150315284 | OPTIMIZED Fc VARIANTS - The present invention relates to a variant Fc region comprising an amino acid substitution at position 238 of the Fc region as compared to a human parent Fc region, wherein the variant Fc region comprises a 238D substitution, wherein the variant Fc region binds FcγRIIb with increased binding affinity compared to a human parent Fc region. | 2015-11-05 |
20150315285 | HUMAN CDR-GRAFTED ANTIBODY AND ANTIBODY FRAGMENT THEREOF - A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient. | 2015-11-05 |
20150315286 | GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF - The present invention provides glycated Amadori products of the CD59 peptide and fragments thereof to be used as tools and among methods for the diagnosis and prognosis of pre-diabetes and diabetes. Certain aspects of the invention include glycated Amadori products of CD59 and fragments thereof to be used for the generation of antibodies and antibody fragments. Still other aspects of the invention include methodologies for the preparation of glycated Amadori products of CD59, fragments thereof, the inventive antibodies, and antibody fragments. | 2015-11-05 |
20150315287 | Genetic Products Differentially Expressed in Tumors and the Use Thereof - According to the invention, gene products expressed in a tumor-associated manner and the nucleic acids coding therefor were identified. The invention relates to the therapy and diagnosis of diseases wherein said gene products expressed in a tumor-associated manner are aberrantly expressed. The invention also relates to proteins, polypeptides and peptides which are expressed in a tumor associated manner and to nucleic acids coding therefor. | 2015-11-05 |
20150315288 | ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF - The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided. | 2015-11-05 |
20150315289 | ANTIBODIES REACTIVE WITH AN EPITOPE LOCATED IN THE N-TERMINAL REGION OF MUC5AC COMPRISING CYSTEINE-RICH SUBDOMAIN 2 (CYS2) - The present invention concerns compositions and methods of use of antibodies or antibody fragments that bind to an epitope located within the second cysteine-rich domain (Cys2, amino acid residues 1575-1725) of MUC5AC. The antibodies bind with high specificity and selectivity to pancreatic cancer and are of use for therapy, detection and/or diagnosis of pancreatic cancer. In preferred embodiments, therapeutic antibody may be conjugated to at least one therapeutic agent, such as | 2015-11-05 |